These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 33441519)

  • 1. [Development of skin squamous cell carcinoma on the scalp in a hydroxycarbamide-treated polycythemia vera patient].
    Suzuki M; Maezima E; Ohnuma T; Kawamura T; Kirito K
    Rinsho Ketsueki; 2020; 61(12):1670-1672. PubMed ID: 33441519
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Dermatologic complications of long-term hydroxyurea therapy].
    Mokni S; Fetoui Ghariani N; Aounallah A; Fathallah N; Boussofara L; Saidi W; Ben Salem C; Sriha B; Belajouza C; Denguezli M; Ghariani N; Nouira R
    Therapie; 2017 Jun; 72(3):391-394. PubMed ID: 27912970
    [No Abstract]   [Full Text] [Related]  

  • 3. Cepeginterferon alfa-2b in the treatment of chronic myeloproliferative diseases.
    Melikyan AL; Subortseva IN; Gilyazitdinova EA; Koloshejnova TI; Pustovaya EI; Egorova EK; Kovrigina AM; Sudarikov AB; Abdullaev AO; Lomaia EG; Siordiya NT; Zaritskey AY; Savchenko VG
    Ter Arkh; 2018 Aug; 90(7):23-29. PubMed ID: 30701919
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk factors for non-melanoma skin cancer in patients with essential thrombocythemia and polycythemia vera.
    Gómez M; Guillem V; Pereira A; Ferrer-Marín F; Álvarez-Larrán A; Kerguelen A; Estrada N; Martínez-López J; Angona A; Amat P; Navarro B; Besses C; Hernández-Boluda JC
    Eur J Haematol; 2016 Mar; 96(3):285-90. PubMed ID: 25996073
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Frequent reduction or absence of detection of the JAK2-mutated clone in JAK2V617F-positive patients within the first years of hydroxyurea therapy.
    Girodon F; Schaeffer C; Cleyrat C; Mounier M; Lafont I; Santos FD; Duval A; Maynadié M; Hermouet S
    Haematologica; 2008 Nov; 93(11):1723-7. PubMed ID: 18728027
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral squamous cell carcinoma during long-term treatment with hydroxyurea.
    De Benedittis M; Petruzzi M; Giardina C; Lo Muzio L; Favia G; Serpico R
    Clin Exp Dermatol; 2004 Nov; 29(6):605-7. PubMed ID: 15550132
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Cutaneous side effects of hydroxyurea treatment for polycythemia vera].
    Hoff NP; Akanay-Diesel S; Pippirs U; Schulte KW; Hanneken S
    Hautarzt; 2009 Oct; 60(10):783-7. PubMed ID: 19756436
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hydroxyurea: The drug of choice for polycythemia vera and essential thrombocythemia.
    Dingli D; Tefferi A
    Curr Hematol Malig Rep; 2006 Jun; 1(2):69-74. PubMed ID: 20425334
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aggressive cutaneous squamous cell carcinoma in a hydroxyurea- and ruxolitinib-pretreated patient with polycythaemia vera.
    Gambichler T; Stockfleth E; Susok L
    J Eur Acad Dermatol Venereol; 2022 Jan; 36 Suppl 1():63-65. PubMed ID: 34855240
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Homoharringtonine is an effective therapy for patients with polycythemia vera or essential thrombocythemia who have failed or were intolerant to hydroxycarbamide or interferon-α therapy.
    Li Y; Zhu J; Ding B
    Int J Clin Oncol; 2013 Oct; 18(5):922-6. PubMed ID: 22898909
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The cutaneous side-effects of hydroxyurea.
    Young HS; Khan AS; Kendra JR; Coulson IH
    Clin Lab Haematol; 2000 Aug; 22(4):229-32. PubMed ID: 11012636
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Busulfan versus hydroxyurea in the treatment of polycythemia vera (PV) and essential thrombocythemia (ET).
    Brodsky I
    Am J Clin Oncol; 1998 Feb; 21(1):105-6. PubMed ID: 9499248
    [No Abstract]   [Full Text] [Related]  

  • 13. Busulfan in patients with polycythemia vera or essential thrombocythemia refractory or intolerant to hydroxyurea.
    Alvarez-Larrán A; Martínez-Avilés L; Hernández-Boluda JC; Ferrer-Marín F; Antelo ML; Burgaleta C; Mata MI; Xicoy B; Martínez-Trillos A; Gómez-Casares MT; Durán MA; Marcote B; Ancochea A; Senín A; Angona A; Gómez M; Vicente V; Cervantes F; Bellosillo B; Besses C
    Ann Hematol; 2014 Dec; 93(12):2037-43. PubMed ID: 24981691
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.
    Nand S; Stock W; Godwin J; Fisher SG
    Am J Hematol; 1996 May; 52(1):42-6. PubMed ID: 8638610
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Historical perspective on the treatment of essential thrombocythemia and polycythemia vera.
    Gilbert HS
    Semin Hematol; 1999 Jan; 36(1 Suppl 2):19-22. PubMed ID: 9930553
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effects of hydroxyurea on PRV-1 expression in patients with essential thrombocythemia and polycythemia vera.
    Johansson P; Ricksten A; Wasslavik C; Johansson B; Andréasson B
    Haematologica; 2004 Oct; 89(10):1264-6. PubMed ID: 15477215
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Non-adherence to treatment with cytoreductive and/or antithrombotic drugs is frequent and associated with an increased risk of complications in patients with polycythemia vera or essential thrombocythemia (OUEST study).
    Le Calloch R; Lacut K; Le Gall-Ianotto C; Nowak E; Abiven M; Tempescul A; Dalbies F; Eveillard JR; Ugo V; Giraudier S; Guillerm G; Lippert E; Berthou C; Ianotto JC
    Haematologica; 2018 Apr; 103(4):607-613. PubMed ID: 29246923
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A patient case highlighting the myriad of cutaneous adverse effects of prolonged use of hydroxyurea.
    Neill B; Ryser T; Neill J; Aires D; Rajpara A
    Dermatol Online J; 2017 Nov; 23(11):. PubMed ID: 29447639
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Leg ulcers in patient affected by polycythemia vera in treatment with hydroxycarbamide. Case report].
    Chiummariello S; Arleo S; Alfano C
    G Chir; 2010 Mar; 31(3):120-3. PubMed ID: 20426925
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nonmelanoma skin cancer associated with Hydroxyurea treatment: Overview of the literature and our own experience.
    Cantisani C; Kiss N; Naqeshbandi AF; Tosti G; Tofani S; Cartoni C; Carmosino I; Cantoresi F
    Dermatol Ther; 2019 Sep; 32(5):e13043. PubMed ID: 31364787
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.